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2Abstract.
Aicardi-Goutieres syndrome (AGS) is an unusual condition that clinically
mimics a congenital viral infection. Several genes have recently been implicated in
the aetiology of this disorder. One of these genes encodes the DNA exonuclease
TREX1. Recent work from Yang, Lindahl and Barnes has provided insight into the
cellular consequence of TREX1-deficiency. They found that TREX1-deficiency
resulted in the intra-cellular accumulation of single stranded DNA resulting in chronic
activation of the DNA damage response network, even in cells from Trex1-mutated
AGS patients. Here, I summarise their findings and discuss them in context with the
other AGS causative genes which encode subunits of the RNase H2 complex. I
describe mechanisms by which the inappropriate intra-cellular accumulation of
nucleic acid species might deleteriously impact upon normal cell cycle progression.
Finally, using the example of Systemic Lupus Erythematosus (SLE), I also summarise
the evidence suggesting that the failure to process intermediates of nucleic acid
metabolism can result in the activation of uncontrolled autoimmunity.
31. Introduction.
In 1984 two French paediatric neurologists, Jean Aicardi and Francoise
Goutieres, described an unusual condition in a Portuguese family characterised by
chronic lymphocyte infiltration into the cerebrospinal fluid (CSF), calcification of the
basal ganglia and early onset progressive severe encephalopathy (brain degeneration)
[1]. Since the clinical sequelae of this condition closely mimicked intra-uterine
infection, cytomegalovirus was originally suspected as the causative agent. But,
detailed serological screening for TORCH (toxoplasmosis, rubella, cytomegalovirus
and herpes simplex) failed to implicate any infectious agent. What made this
condition even more intriguing was the birth of a second affected child to the
consanguineous parents, strongly suggesting an autosomal recessive disorder.
Subsequent studies on other patients confirmed the heritable nature of this condition
and extended the clinical spectrum to include progressive microcephaly (reduced
brain size), cutaneous lesions on the extremities (fingers, toes, ears) reminiscent of
chilblain’s and increased levels of -interferon (-INF) in the CSF and blood [2].
Since its original description in 1984, several Aicardi-Goutieres syndrome (AGS)
susceptibility loci have been identified from mapping studies in different families
(Table 1). In the Summer of 2006, following extensive genetic analysis of multiple
families, causative mutations were described for AGS in several distinct genes, one of
which encoded the major 3’-5’ DNA exonuclease in mammalian cells DNase
III/TREX1 (Three prime repair exonuclease I) (Table 1)[3] [4]. Recent work from the
Yang, Lindahl and Barnes has uncovered an exciting link between defective DNase
III/TREX1 (hereafter referred to TREX1), the accumulation of excessive single
stranded DNA (ssDNA) in the cytoplasm and chronic activation of the ATM-
dependent DNA damage response [5]. This work follows-on directly from
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within a complex with NM23-H1 endonuclease where they function together to
degrade DNA in a caspase-independent cell death pathway [6]. Together these
findings provide information on the biologically relevant function of TREX1 and hint
at a provocative mechanistic explanation for how mutations in a DNA exonuclease
can result in a complex human disorder that mimics a congenital viral infection.
2. A brief summary of mammalian DNA exonucleases.
The majority of DNA exonuclease activity in mammalian cell extracts derives
from two distinct nuclear enzymes originally designated DNase III (3’-5’) and DNase
IV (5’-3’). Exonuclease I (EXO1) also encodes a 5’-3’ exonuclease that functions
mainly in mismatch repair and recombination [7]. These activities are distinct from
the DNA endonucleases DNase I and DNase II. DNase IV was subsequently renamed
Flap Endonuclease 1 (FEN1), and was shown to function in the processing of 5’
single stranded overhangs that arise during lagging-strand DNA replication, DNA
repair and recombination [8,9]. DNase III (TREX1) was found to encode a non-
processive 3’-5’ DNA exonuclease with a preference for ssDNA or mispaired 3’
termini [10,11]. TREX1 shares homology to the E. coli DnaQ/MutD editing subunit
of the replicative DNA polymerase III holoenzyme [12]. Since two of the principal
mammalian nuclear DNA polymerases, Pol and Pol, do not possess intrinsic
proofreading 3’exonuclease activity, it was originally thought that TREX1 may serve
to excise mismatched dNTP’s during lagging strand DNA synthesis (Pol-dependent)
or gap filling during base excision repair (BER, Pol-dependent [13,14]In fact,
TREX1 was shown to remove a 3’mismatch in an in vitro BER assay reconstituted
with Pol [12]. The functional/biological significance of this remained unclear as
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apurinic-apyrimidinic (AP) endonuclease, have been implicated in BER.
TREX2 shares significant (approx 44%) amino acid identity with TREX1,
although it lacks the C-terminal 68 amino acid extension found in TREX1. Similarly
to TREX1, TREX2 also functions as a 3’-5’ exonuclease [13]. The precise biological
function of TREX2 is currently unclear although a possible role in mediating genomic
stability has been suggested [15]. The crystal structure of Trex1 has recently been
described and readers are referred to these studies for in-depth description of TREX1
structure-function analysis [16,17].
3. A mouse model for TREX1-deficiency.
A direct, biologically relevant role for TREX1 in BER was further put in
doubt when TREX1-/- mice generated in the Big Blue indicator background failed to
exhibit an increased spontaneous mutation frequency [18]. In fact, TREX1-/- mice did
not exhibit increased tumour incidence. Furthermore, TREX1-/- mouse embryonic
fibroblasts (MEFs) did not exhibit an increased sister chromatid exchange frequency
(typical of XRCC1-defective hamster cells) or sensitivity towards hydrogen peroxide
or ionising radiation (IR) [18]. Although TREX1-/- mice were born at Mendelian
frequencies, suggesting that the gene was non-essential, they exhibited a significantly
reduced life span with spontaneous development of inflammatory myocarditis
(inflammation of the muscle wall of the heart), progressive dilated cardiomyopathy
and consequent circulatory failure [18]. The inflammatory myocarditis found in
TREX1-/- animals was consistent with an autoimmune aetiology since it occurred in
pathogen-free animals.
64. TREX1-deficiency, ssDNA and the DNA damage response.
The exact mechanism of TREX1-deficient disease has remained obscure
despite causing AGS in human [4]. Using TREX1-/- MEFs and AGS-derived patient
cells, Yang et al have uncovered interesting cellular consequences of TREX1-
deficiency that help shed light on this issue [5]. Firstly, they corroborated the recent
observation by the Lieberman group that TREX1 predominantly localises to the
cytoplasm, specifically the endoplasmic reticulum (ER), which is somewhat
unexpected for a DNA-specific exonuclease [5,6]. Interestingly, TREX1 was found to
localise to the nucleus at replication (BrdU positive) foci following DNA damage.
They also found that TREX1-/- MEFs do not progress normally through the cell
cycle, instead exhibiting a reduced S-phase population and accumulation in G1.
Furthermore, following treatment with IR, TREX1-/- MEFs failed to arrest properly
in S and G2/M-phases of the cell cycle. Molecular dissection of these cellular
phenotypes showed that TREX1-/- MEFs exhibited spontaneously increased levels of
both p53 and p21 suggestive of chronic activation of the DNA damage response
machinery. Interestingly, TREX1-/- MEFs also exhibited a significantly reduced
endogenous level of CHK2. Chemical inhibition of ATM kinase activity using the
specific ATM inhibitor, KU-55933, restored CHK2 expression levels. Although the
mechanism remains unclear, collectively these data indicate chronic ATM-mediated
checkpoint activation in TREX1-/- MEFs in the absence of exogenous DNA damage
[5].
Since TREX1 was found to localise to BrdU positive foci in S phase cells
exposed to DNA damage, coupled with its known preference for ssDNA as a
substrate, Yang et al reasoned that TREX1 likely acts on ssDNA generated during
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Using an antibody specific to ssDNA, TREX1-/- MEFs showed increased levels of
ssDNA but, strikingly, it was almost exclusively extranuclear. Co-localisation with
the ER-specific marker calreticulin showed that the ssDNA was associated with the
ER. Furthermore, cellular fractionation studies showed that cytoplasmic extracts from
TREX1-/- MEFs specifically contain ssDNA polynucleotides of between 60-65 bases
in size. Using BrdU labelling under non-denaturing conditions, Yang et al proposed
that the ER-associated ssDNA was derived from S phase cells [5]. Moreover, primary
fibroblasts from AGS patients with a homozygous mutation in Trex1 exhibited a
similar cell cycle profile as TREX1-/- MEFs (low S-phase and accumulation at G1),
along with increased p53 and p21 levels, reduced CHK2 expression and increased
ER-associated ssDNA. Together, these data suggest that TREX1-deficiency results in
the accumulation of excessive amounts of short ssDNA oligonucleoides within the
cytoplasm of replicating cells, which somehow results in chronic activation of the
DNA damage response-signalling network [5].
5. Is there a functional link between TREX1-deficiency and the other AGS
causative genes?
AGS mimics congenital viral infection. In fact, exclusion of perinatal infection
is one of the diagnostic criteria for this disorder [1,2]. TREX1-deficiency leads to the
inappropriate accumulation of ssDNA within the cell, a factor presumed to contribute
to the aetiology and progression of this condition (see below). Why should or how can
excessive amounts of DNA within a cell result in a pathological condition?
Furthermore, what of the other AGS causative genes (Table 1)? Do they also play a
role in processing nucleic acids? Crow and colleagues, along with implicating
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subunits of the RNase H2 complex in several non-Trex1-mutated AGS families [3,4].
The equivalent complex in S. cerevisiae (Rnh2Ap- Rnh2Bp- Rnh2Cp)
endonucleolytically cleaves ribonucleotides from RNA:DNA duplexes [19]. The
RNase H2 complex is thought to specifically function in the removal of lagging-
strand Okazaki fragment RNA primers during DNA replication as well as in the
excision of mis-incorporated ribonucleotides from DNA duplexes [19]. Therefore, the
identification of further AGS causative mutations in genes that co-ordinately function
as a nuclease (ribonuclease in this case) reinforces the notion that the potential
excessive intra-cellular accumulation of nucleic acid species (ssDNA, DNA:RNA
duplexes, even ribonucleotide containing DNA:DNA duplexes) may contribute to the
pathology of AGS [3-5].
6. TREX1 and cell death: cutting DNA for a reason.
TREX1 activity has also been implicated in a specific caspase-independent
cell death pathway utilised by cytotoxic T cells and Natural Killer cells during the
immune response [6]. Granzyme A (GzmA) is a serine protease that once delivered
into target cells by perforin via immunological synapse initiates a cell death pathway
that morphologically resembles caspase-dependent apoptosis [20,21]. GzmA
mediated cell death is characterised by the appearance of ssDNA, as opposed to the
dsDNA fragmentation typical of apoptosis. Once GzmA is introduced into cells it
cleaves SET, an inhibitor of the NM23-H1 endonucelase resulting in NM23-H1
activation [22]. SET and NM23-H1 reside in the ER in a large complex (SET
complex) one of whose components has recently been shown to be TREX1 [6]. It is
thought that NM23-H1 and TREX1 work co-ordinately whereby activated NM23-H1
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nucleotides from the nicked 3’ end to prevent the BER pathway from rapidly
rejoining the nicks [6]. The SET complex is thought to play an important role in the
defence against viruses and tumour cells that have evolved strategies for evading
caspase-mediated apoptosis [23]. Silencing of Trex1 (siRNA) can inhibit GzmA-
mediated cell death [6]. Therefore, TREX1 clearly has a role in some cell types
outside of processing DNA replication intermediates.
7. A mechanism for a role of TREX1-deficiency and RNase H2-deficiency in
autoimmune disease.
A member of the Toll-like receptor family, TLR9, is associated with the ER of
several immune system cell types (eg. macrophages), where it responds to
endocytosed DNA (including ssDNA species) containing unmethylated CpG residues
[24,25]. TLR9 normally serves as a pathogen sensor by detecting unmethylated DNA
that is characteristically over-represented in bacterial DNA compared to mammals
[25]. The S-phase-derived ER-associated ssDNA observed by Yang et al to
accumulate in TREX1-/- MEFs and AGS patient cells is unlikely to have undergone
extensive de novo methylation at CpG residues [5]. Therefore, it is possible that it
may result in, or contribute to uncontrolled activation of the innate immune system
with pathological consequences (autoimmune reaction). Similarly, as Trex1-
deficiency inhibits GzmA-mediated cell death, this could indirectly result in the
failure to remove autoreactive cytotoxic T cells whose accumulation could also
contribute to autoimmunity [6].
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A diagnostic clinical feature of AGS is elevated levels of -IFN in the CSF
and blood suggestive of viral infection [2]. It is known that dsRNA and dsDNA can
activate the innate immune system and induce -IFN production [26]. Reverse
transcription, involving the formation of DNA:RNA hybrids, is an essential step
during retroviral propagation. Failure of the RNase H2 complex to adequately clear
DNA:RNA Okazaki fragments could conceivably result in the accumulation of
nucleic acid species that mimic a retroviral infection. Although, it should be noted
that the accumulation of intracellular nucleic acids in non-Trex1 mutated AGS patient
cells has not yet been formally demonstrated.
How does chronic activation of the DNA damage response impact on immune
system function? An elegant study from Gasser and colleagues has shown that some
stimulatory receptors (NKG2D receptors) of the innate immune system are activated
in an ATM, ATR and CHK1-dependent manner [27]. A proposed role for this
NKG2D receptor up-regulation is to enable the innate immune system to distinguish
between normal (self) and diseased (infected/transformed cells) [28]. Interestingly,
chronic activation of the DNA damage response has recently been found to precede
malignant transformation [29-31]. It is particularly interesting to note that cancer
predisposition has not been observed in AGS despite several patients being in the
third decade of life [2]. It is tempting to think that this may be because the innate
immune system in AGS individuals is already primed or activated (inappropriately) to
target non-self (i.e. transformed) cells.
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8. Systemic Lupus Erythematosus: a precedent for defective nuclease activity in
mediating autoimmunity.
Systemic Lupus Erythematosus (SLE) is a multifactorial, genetically
heterogeneous, systemic autoimmune disease characterised by the presence of anti-
nuclear antibodies (ANA) directed against entire nucleosomes and even naked DNA
[32,33]. It is thought that the resulting immune complexes accumulate in joints,
glomeruli and blood vessels manifesting as combined arthritis, glomerulophritis
(kidney disease) and vasculitis respectively. The precise cause of SLE is unknown
although it has been suggested that the failure to adequately clear protein-DNA
complexes liberated particularly during cell death may underlie the initiation and
progression of this disease [33]. One of the many genes implicated in SLE is the DNA
endonuclease DNase I (reviewed in [34]). DNase I represents the major nuclease
activity present in serum, urine and other secreta. DNase I-/- mice recapitulate the
classical clinical spectrum of SLE including ANA production, deposition of immune
complexes in glomeruli and overt glomerulophritis [35]. Mutations in DNase I that
significantly disrupt its enzymatic activity have also been found in other SLE patients
[36]. Therefore, precedent for a functional association between compromised nuclease
function, in this case a DNA endonuclease, and a systemic autoimmune disorder
exists in the form of SLE. Interestingly, several monoallelic mutations in Trex1 have
recently been described in individuals with SLE and also in a variant of this condition,
Familial Chilblain Lupus, which presents with ulcerating lesions of the skin in acral
locations (fingers, ears and toes) [37,38].
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9. Some outstanding questions.
The study by Yang, Lindahl and Barnes concerning the cellular consequences
of TREX1-deficiency raises many questions that are likely to form the basis for
further investigation [5]. For example, is the intracellular accumulation of ssDNA a
cellular feature of non-Trex1-mutated AGS? Moreover, if the ER-associated ssDNA
that accumulates in the absence of TREX1 activity is derived from S-phase, how does
it end up at the ER? Are replication forks particularly susceptible to collapse, even in
the absence of exogenous DNA damage, in TREX1-deficient cells? If so, is it the
collapse of these replication forks that ultimately triggers the DNA damage response?
After all, TREX1-/- MEFs and TREX1-deficient AGS fibroblasts have a very low S-
phase population [5]. DNA fibre technology will no doubt aid in addressing these
issues.
Furthermore, p21 and p53 expression are clearly induced in the absence of
TREX1 and consequently cells accumulate in G1. But, these cells can in fact cycle,
albeit at a reduced rate [5]. This seems somewhat counter-intuitive if the chronically
activated DNA damage-signalling pathway is fully functional. Yang et al show that
CHK2 protein levels are reduced, in an ATM-dependent manner, in the absence of
TREX1 [5]. This suggests that the TREX1-deficient cells actively target a key
effector of the DNA damage-signalling network to possibly de-sensitise the cell cycle
checkpoint(s) facilitating some degree of growth. Interestingly, ATM levels in the
AGS primary fibroblasts also appear to be reduced (Figure 5B [5]). Whilst chronic
activation of the DNA damage response has been observed in other human disorders,
for example Hutchinson-Gilford Progeroid syndrome, cells from these patients grow
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extremely badly in culture [39,40]. The mechanism of the cell cycle progression in the
absence of TREX1 activity awaits further characterisation at the molecular level.
One other aspect of the DNA damage response that is worthy of deeper
investigation in the context of TREX1-deficiency (and RNase H deficiency) is the
question of ATR’s contribution to the cellular phenotype observed by Yang et al [5].
After all, ssDNA is the lesion to which ATR responds [41,42]. Abundant evidence
suggests that ATM is activated by dsDNA. It would be informative to examine ATM
activation directly (eg. ATM-Ser-1981 autophosphorylation) in TREX1-deficienct
AGS cells to gain insight into the precise level of contribution of active ATM to the
cellular phenotypes observed. It is becoming increasing evident that the interplay and
functional overlap between ATM signalling and ATR signalling is greater than had
previously been assumed. Complementary studies from the Jackson and Jeggo
laboratories has provided evidence suggesting that ATM and ATR do not function as
independent signalling pathways to distinct forms of DNA damage in human cells,
but actually operate in concert [43,44]. There is increasing evidence that both CHK1
and CHK2 activities are required for a functional cell cycle arrest at G2 [43,44]. It is
very interesting to note that whilst Yang et al do observe CHK1 phosphorylation
following HU treatment in TREX1-/- MEFs, this signal is much reduced compared to
wild type MEFs (Figure 3B [5]). This could be indicative of compromised ATR-
pathway function in the absence of TREX1 or may simply reflect the low S-phase
content of these cells. But, this response is reminiscent of the ‘leaky’ signalling
responses observed in ATR-mutated Seckel syndrome cells [42,46]. It would be
interesting to examine this in more detail using other ATR-pathway specific assays
[45-47]. There is strong evidence to suggest that a compromised ATR-pathway is
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associated with microcephaly in many human disorders [45-51], which provocatively,
is frequently observed in AGS [2]. Whilst it is entirely speculative to suggest that this
may potentially reflect compromised ATR-pathway function in AGS, it would be
relatively straight forward to investigate this.
It remains to be determined why TREX1-/- mice do not reiterate the clinical
phenotype of AGS, or conversely, why myocarditis is not a frequent clinical feature
of AGS patients? Much remains to be uncovered about the cellular and clinical
consequences of Trex1-deficiency. For example, novel monoallelic mutations in
Trex1 have also been described as the cause of autosomal dominant Retinal
Vasculopathy with Cerebral Leukodystrophy syndrome (RVCL) [52]. RVCL does
not resemble AGS or SLE. Individuals with RVCL suffer visual loss, stroke and
dementia. Interestingly, RVCL causative Trex1 mutations do not affect Trex1
exonuclease activity but impact on Trex1 intra-cellular localisation [52]. Work on
TREX1 is currently uncovering novel interacting proteins and should provide more
information on the multifunctional nature of this enzyme [16]. Finally, it will be
important to uncover the extent of functional overlap, if any, between TREX1 and
Trex2. Since further AGS causative genes await identification, it is conceivable that
mutations in Trex2 could result in AGS (Table 1). I’m sure this question is actively
being pursued.
10. The Future.
The story of TREX1 and AGS illustrates the power of the combined efforts of
clinical geneticists, immunologists, biochemists and cell biologists in elucidating the
molecular aetiology of a complex human disorder. If we can understand the molecular
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origin of a disorder we can improve patient management and ultimately develop a
curative therapy. A pertinent example is the use of DNase I-therapy in SLE (reviewed
in [53]). Although initial optimism for the utility of this approach in SLE has been
tempered by recent studies, nuclease treatment has been employed in the management
of Cystic Fibrosis, a condition where the airways become blocked with viscous mucus
containing very high concentrations of bacterial DNA (reviewed in [54]). TREX1-
deficiency and AGS offer a fascinating example of why the cell must take extreme
care in cleaning up its nucleic acid debris/metabolic intermediates, as it can lead to
unexpected and unwelcome consequences. As is true for all ‘hot topics’ in research,
much more information remains to be uncovered regarding Trex1, its physiological
role and its contribution to the pathology of AGS.
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Figure Legends.
Figure 1.
The structural domains of TREX1. Trex1 functions as a homodimer and its
crystal structure has recently been solved [16,17]. For a detailed discussion of Trex1
structure-function analysis readers are referred to the studies by Brucet and colleagues
and de Silva and colleagues [16,17]. Exo 1-3 represent the exonuclease domains
which co-ordinate Mg+2 which is essential for catalysis. PPII refers to the polyproline
II motif implicated in mediating protein-protein interactions with proline-binding
domain containing proteins. In fact, PPII has been shown to be required for the
interaction of Trex1 with the transcription factor CA150 [16]. The functional
significance of this interaction remains to be clarified. TMH is the transmembrane
helix that traverses the ER membrane proposed to function in anchoring TREX1 to
the ER [37]. Removal of the TMH is thought to be required for translocation of
TREX1 to the nucleus. Trex1 mutations specifically affecting TREX1 intra-cellular
localisation cause autosomal dominant Retinal Vasculopathy with Cerebral
Leukodystrophy syndrome [52]. Aicardi-Goutieres syndrome, Systemic Lupus
Erythematosus and Familial Chilblain Lupus causative mutations are distributed
throughout the Trex1 gene. Work by de Silva and colleagues using TREX1 crystal
structures illustrate how certain AGS causative Trex1 mutations affect TREX1 protein
function at the molecular level [17].
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Table 1.
A summary of the genes known to be involved in Aicardi-Goutieres
syndrome.
Table
1
AGS locus Gene Chromosome Frequency of
mutation
in AGS
AGS1 Trex1 3p21.31 25%
AGS2 RNASEH2B 13q14.3 40%
AGS3 RNASEH2C 11q13.2 14%
AGS4 RNASEH2A 19p13.13 4%
No mutation identified in any of the above 17%
18
References.
[1] J. Aicardi and F. Goutieres A progressive familial encephalopathy in
infancy with calcifications of the basal ganglia and chronic cerebrospinal
fluid lymphocytosis., Ann Neurol 15 (1984) 49-54.
[2] G. Rice, T. Patrick, R. Parmar, C.F. Taylor, A. Aeby, J. Aicardi, R.
Artuch, S.A. Montalto, C.A. Bacino, B. Barroso, P. Baxter, W.S. Benko,
C. Bergmann, E. Bertini, R. Biancheri, E.M. Blair, N. Blau, D.T.
Bonthron, T. Briggs, L.A. Brueton, H.G. Brunner, C.J. Burke, I.M. Carr,
D.R. Carvalho, K.E. Chandler, H.-J. Christen, P.C. Corry, F.M. Cowan,
H. Cox, S. D Arrigo, J. Dean, C. De Laet, C. De Praeter, C. Déry, C.D.
Ferrie, K. Flintoff, S.G.M. Frints, A. Garcia-Cazorla, B. Gener, C. Goizet,
F. Goutières, A.J. Green, A. Guët, B.C.J. Hamel, B.E. Hayward, A.
Heiberg, R.C. Hennekam, M. Husson, A.P. Jackson, R. Jayatunga, Y.-H.
Jiang, S.G. Kant, A. Kao, M.D. King, H.M. Kingston, J. Klepper, M.S.
van der Knaap, A.J. Kornberg, D. Kotzot, W. Kratzer, D. Lacombe, L.
Lagae, P.G. Landrieu, G. Lanzi, A. Leitch, M.J. Lim, J.H. Livingston,
C.M. Lourenco, E.G.H. Lyall, S.A. Lynch, M.J. Lyons, D. Marom, J.P.
McClure, R. McWilliam, S.B. Melancon, L.D. Mewasingh, M.-L.
Moutard, K.K. Nischal, J.R. Østergaard, J. Prendiville, M. Rasmussen,
R.C. Rogers, D. Roland, E.M. Rosser, K. Rostasy, A. Roubertie, A.
Sanchis, R. Schiffmann, S. Scholl-Bürgi, S. Seal, S.A. Shalev, C.S.
Corcoles, G.P. Sinha, D. Soler, R. Spiegel, J.B.P. Stephenson, U. Tacke,
T.Y. Tan, M. Till, J.L. Tolmie, P. Tomlin, F. Vagnarelli, E.M. Valente,
R.N.A. Van Coster, N. Van der Aa, A. Vanderver, J.S.H. Vles, T. Voit, E.
Wassmer, B. Weschke, M.L. Whiteford, M.A.A. Willemsen, A. Zankl,
S.M. Zuberi, S. Orcesi, E. Fazzi, P. Lebon and Y.J. Crow Clinical and
Molecular Phenotype of Aicardi-Goutières Syndrome, American journal
of human genetics 81 (2007) 713-725.
[3] Y.J. Crow, A. Leitch, B.E. Hayward, A. Garner, R. Parmar, E. Griffith,
M. Ali, C. Semple, J. Aicardi, R. Babul-Hirji, C. Baumann, P. Baxter, E.
Bertini, K.E. Chandler, D. Chitayat, D. Cau, C. Dery, E. Fazzi, C. Goizet,
M.D. King, J. Klepper, D. Lacombe, G. Lanzi, H. Lyall, M.L. Martinez-
Frias, M. Mathieu, C. McKeown, A. Monier, Y. Oade, O.W. Quarrell,
C.D. Rittey, R.C. Rogers, A. Sanchis, J.B.P. Stephenson, U. Tacke, M.
Till, J.L. Tolmie, P. Tomlin, T. Voit, B. Weschke, C.G. Woods, P. Lebon,
D.T. Bonthron, C.P. Ponting and A.P. Jackson Mutations in genes
encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome
and mimic congenital viral brain infection, Nat Genet 38 (2006) 910-916.
[4] Y.J. Crow, B.E. Hayward, R. Parmar, P. Robins, A. Leitch, M. Ali, D.N.
Black, H. van Bokhoven, H.G. Brunner, B.C. Hamel, P.C. Corry, F.M.
Cowan, S.G. Frints, J. Klepper, J.H. Livingston, S.A. Lynch, R.F. Massey,
J.F. Meritet, J.L. Michaud, G. Ponsot, T. Voit, P. Lebon, D.T. Bonthron,
A.P. Jackson, D.E. Barnes and T. Lindahl Mutations in the gene encoding
the 3[prime]-5[prime] DNA exonuclease TREX1 cause Aicardi-Goutieres
syndrome at the AGS1 locus, Nat Genet 38 (2006) 917-920.
19
[5] Y.-G. Yang, T. Lindahl and D.E. Barnes Trex1 Exonuclease Degrades
ssDNA to Prevent Chronic Checkpoint Activation and Autoimmune
Disease, Cell 131 (2007) 873-886.
[6] D. Chowdhury, P.J. Beresford, P. Zhu, D. Zhang, J.-S. Sung, B. Demple,
F.W. Perrino and J. Lieberman The Exonuclease TREX1 Is in the SET
Complex and Acts in Concert with NM23-H1 to Degrade DNA during
Granzyme A-Mediated Cell Death, Molecular Cell 23 (2006) 133-142.
[7] P.T. Tran, N. Erdeniz, L.S. Symington and R.M. Liskay EXO1-A multi-
tasking eukaryotic nuclease, DNA Repair 3 (2004) 1549-1559.
[8] T. Lindahl, J.A. Gally and G.M. Edelman Deoxyribonuclease IV: A New
Exonuclease from Mammalian Tissues, Proceedings of the National
Academy of Sciences 62 (1969) 597-603.
[9] Y. Liu, H.-I. Kao and R.A. Bambara FLAP ENDONUCLEASE 1: A
Central Component of DNA Metabolism, Annual Review of Biochemistry
73 (2004) 589-615.
[10] T. Lindahl, J.A. Gally and G.M. Edelman Properties of
Deoxyribonuclease III from Mammalian Tissues, J. Biol. Chem. 244
(1969) 5014-5019.
[11] I.V. Shevelev and U. Hubscher The 3[prime]-5[prime] exonucleases, Nat
Rev Mol Cell Biol 3 (2002) 364-376.
[12] M. Höss, P. Robins, P. Naven, D. Pappin, J. Sgouros and T. Lindahl A
human DNA editing enzyme homologous to the Escherichia coli
DnaQ/MutD protein. EMBO Journal 18 (1999) 3868–3875.
[13] D.J. Mazur and F.W. Perrino Identification and Expression of the
TREX1 and TREX2 cDNA Sequences Encoding Mammalian 3'right-
arrow5' Exonucleases, J. Biol. Chem. 274 (1999) 19655-19660.
[14] D.J. Mazur and F.W. Perrino Excision of 3' Termini by the Trex1 and
TREX2 3'-5' Exonucleases. Characterization of the recombinant proteins,
J. Biol. Chem. 276 (2001) 17022-17029.
[15] M.-J. Chen, S.-M. Ma, L.C. Dumitrache and P. Hasty Biochemical and
cellular characteristics of the 3' -> 5' exonuclease TREX2, Nucl. Acids
Res. 35 (2007) 2682-2694.
[16] M. Brucet, J. Querol-Audi, M. Serra, X. Ramirez-Espain, K. Bertlik, L.
Ruiz, J. Lloberas, M.J. Macias, I. Fita and A. Celada Structure of the
Dimeric Exonuclease TREX1 in Complex with DNA Displays a Proline-
rich Binding Site for WW Domains, J. Biol. Chem. 282 (2007) 14547-
14557.
[17] U. de Silva, S. Choudhury, S.L. Bailey, S. Harvey, F.W. Perrino and T.
Hollis The Crystal Structure of TREX1 Explains the 3' Nucleotide
Specificity and Reveals a Polyproline II Helix for Protein Partnering, J.
Biol. Chem. 282 (2007) 10537-10543.
[18] M. Morita, G. Stamp, P. Robins, A. Dulic, I. Rosewell, G. Hrivnak, G.
Daly, T. Lindahl and D.E. Barnes Gene-Targeted Mice Lacking the Trex1
(DNase III) 3'->5' DNA Exonuclease Develop Inflammatory Myocarditis,
Mol. Cell. Biol. 24 (2004) 6719-6727.
[19] J. Qiu, Y. Qian, P. Frank, U. Wintersberger and B. Shen Saccharomyces
cerevisiae RNase H(35) Functions in RNA Primer Removal during
Lagging-Strand DNA Synthesis, Most Efficiently in Cooperation with
Rad27 Nuclease, Mol. Cell. Biol. 19 (1999) 8361-8371.
20
[20] G.M. Griffiths Endocytosing the death sentence, J. Cell Biol. 160 (2003)
155-156.
[21] J. Lieberman The ABCs of granule-mediated cytotoxicity: new weapons
in the arsenal, Nat Rev Immunol 3 (2003) 361-370.
[22] D. Martinvalet, P. Zhu and J. Lieberman Granzyme A Induces Caspase-
Independent Mitochondrial Damage, a Required First Step for Apoptosis,
Immunity 22 (2005) 355-370.
[23] J. Lieberman and Z. Fan Nuclear war: the granzyme A-bomb, Current
Opinion in Immunology 15 (2003) 553-559.
[24] S. Akira, S. Uematsu and O. Takeuchi Pathogen Recognition and Innate
Immunity, Cell 124 (2006) 783-801.
[25] A. Takaoka, Z. Wang, M.K. Choi, H. Yanai, H. Negishi, T. Ban, Y. Lu, M.
Miyagishi, T. Kodama, K. Honda, Y. Ohba and T. Taniguchi DAI (DLM-
1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune
response, Nature 448 (2007) 501-505.
[26] T. Kawai and S. Akira Innate immune recognition of viral infection, Nat
Immunol 7 (2006) 131-137.
[27] S. Gasser, S. Orsulic, E.J. Brown and D.H. Raulet The DNA damage
pathway regulates innate immune system ligands of the NKG2D receptor,
Nature 436 (2005) 1186-1190.
[28] D.H. Raulet Roles of the NKG2D immunoreceptor and its ligands, Nat
Rev Immunol 3 (2003) 781-790.
[29] R.A. DiTullio, T.A. Mochan, M. Venere, J. Bartkova, M. Sehested, J.
Bartek and T.D. Halazonetis 53BP1 functions in an ATM-dependent
checkpoint pathway that is constitutively activated in human cancer, Nat
Cell Biol 4 (2002) 998-1002.
[30] J. Bartek, J. Bartkova and J. Lukas DNA damage signalling guards
against activated oncogenes and tumour progression, Oncogene 26 7773-
7779.
[31] J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P.
Guldberg, M. Sehested, J.M. Nesland, C. Lukas, T. Orntoft, J. Lukas and
J. Bartek DNA damage response as a candidate anti-cancer barrier in
early human tumorigenesis, Nature 434 (2005) 864-870.
[32] B. Rhodes and T.J. Vyse General aspects of the genetics of SLE,
Autoimmunity 40 (2007) 550-559.
[33] T.J. Vyse and B.L. Kotzin Genetic susceptibility to Systemic Lupus
Erythrematosis, Annual Review of Immunology 16 (1998) 261-292.
[34] M.J. Walport Lupus, DNase and defective disposal of cellular debris, Nat
Genet 25 (2000) 135-136.
[35] M. Napirei, H. Karsunky, B. Zevnik, H. Stephan, H.G. Mannherz and T.
Moroy Features of systemic lupus erythematosus in Dnase1-deficient
mice, Nat Genet 25 (2000) 177-181.
[36] K. Yasutomo, T. Horiuchi, S. Kagami, H. Tsukamoto, C. Hashimura, M.
Urushihara and Y. Kuroda Mutation of DNASE1 in people with systemic
lupus erythematosus, Nat Genet 28 (2001) 313-314.
[37] M.A. Lee-Kirsch, M. Gong, D. Chowdhury, L. Senenko, K. Engel, Y.-A.
Lee, U. de Silva, S.L. Bailey, T. Witte, T.J. Vyse, J. Kere, C. Pfeiffer, S.
Harvey, A. Wong, S. Koskenmies, O. Hummel, K. Rohde, R.E. Schmidt,
A.F. Dominiczak, M. Gahr, T. Hollis, F.W. Perrino, J. Lieberman and N.
Hubner Mutations in the gene encoding the 3[prime]-5[prime] DNA
21
exonuclease TREX1 are associated with systemic lupus erythematosus,
Nat Genet 39 (2007) 1065-1067.
[38] M.A. Lee-Kirsch, D. Chowdhury, S. Harvey, M. Gong, L. Senenko, K.
Engel, C. Pfeiffer, T. Hollis, M. Gahr, F. Perrino, J. Lieberman and N.
Hubner A mutation in TREX1 that impairs susceptibility to granzyme A-
mediated cell death underlies familial chilblain lupus, Journal of
Molecular Medicine 85 (2007) 531-537.
[39] Y. Liu, A. Rusinol, M. Sinensky, Y. Wang and Y. Zou DNA damage
responses in progeroid syndromes arise from defective maturation of
prelamin A, J Cell Sci 119 (2006) 4644-4649.
[40] B. Liu, J. Wang, K.M. Chan, W.M. Tjia, W. Deng, X. Guan, J.-d. Huang,
K.M. Li, P.Y. Chau, D.J. Chen, D. Pei, A.M. Pendas, J. Cadinanos, C.
Lopez-Otin, H.F. Tse, C. Hutchison, J. Chen, Y. Cao, K.S.E. Cheah, K.
Tryggvason and Z. Zhou Genomic instability in laminopathy-based
premature aging, Nat Med 11 (2005) 780-785.
[41] L. Zou, D. Liu and S.J. Elledge Replication protein A-mediated
recruitment and activation of Rad17 complexes, Proc Natl Acad Sci U S A
100 (2003) 13827-13832.
[42] L. Zou and S.J. Elledge Sensing DNA damage through ATRIP
recognition of RPA-ssDNA complexes, Science 300 (2003) 1542-1548.
[43] A. Jazayeri, J. Falck, C. Lukas, J. Bartek, G.C.M. Smith, J. Lukas and
S.P. Jackson ATM- and cell cycle-dependent regulation of ATR in
response to DNA double-strand breaks, Nat Cell Biol 8 (2006) 37-45.
[44] T. Stiff, S. Walker, K. Cerosaletti, A. Goodarzi, E. Petermann, P.
Concannon, M. O'Driscoll and P. Jeggo ATR-dependent phosphorylation
and activation of ATM in response to UV treatment or replication fork
stalling, EMBO J. 25 (2006) 5775–5782.
[45] T. Stiff, Reis, C, Alderton, G.K, Woodbine, L, O'Driscoll, M, Jeggo, P.A
Nbs1 is required for ATR-dependent phosphorylation events., EMBO J
24 (2005) 199-208.
[46] G.K. Alderton, Galbiati, L, Griffith, E, Surinya, K.H, Neitzel, H, Jackson,
A.P, Jeggo, P.A, O'Driscoll, M. Regulation of mitotic entry by
microcephalin and its overlap with ATR signalling, Nature Cell Biology 8
(2006) 725-733.
[47] G.K. Alderton, Joenje, H, Varon, R, Borglum, A D, Jeggo, P A,
O'Driscoll, M. Seckel syndrome exhibits cellular features demonstrating
defects in the ATR signalling pathway, Human Molecular Genetics 13
(2004) 3127-3138.
[48] M. O'Driscoll, V.L. Ruiz-Perez, C.G. Woods, P.A. Jeggo and J.A.
Goodship A splicing mutation affecting expression of ataxia-telangiectasia
and Rad3-related protein (ATR) results in Seckel syndrome, Nature
Genetics 33 (2003) 497-501.
[49] M. O'Driscoll and P.A. Jeggo Clinical Impact of ATR Checkpoint
Signalling Failure in Humans, Cell Cycle 2 (2003) 194-195.
[50] E. Griffith, S. Walker, C.-A. Martin, P. Vagnarelli, T. Stiff, B. Vernay,
N.A. Sanna, A. Saggar, B. Hamel, W.C. Earnshaw, P.A. Jeggo, A.P.
Jackson and M. O'Driscoll Mutations in pericentrin cause Seckel
syndrome with defective ATR-dependent DNA damage signaling, Nat
Genet advanced online publication (2007).
22
[51] M. O Driscoll, W.B. Dobyns, J.M. van Hagen and P.A. Jeggo Cellular and
Clinical Impact of Haploinsufficiency for Genes Involved in ATR
Signaling, American journal of human genetics 81 (2007) 77-86.
[52] A. Richards, A.M.J.M. van den Maagdenberg, J.C. Jen, D. Kavanagh, P.
Bertram, D. Spitzer, M.K. Liszewski, M.-L. Barilla-LaBarca, G.M.
Terwindt, Y. Kasai, M. McLellan, M.G. Grand, K.R.J. Vanmolkot, B. de
Vries, J. Wan, M.J. Kane, H. Mamsa, R. Schafer, A.H. Stam, J. Haan,
P.T.V.M. de Jong, C.W. Storimans, M.J. van Schooneveld, J.A.
Oosterhuis, A. Gschwendter, M. Dichgans, K.E. Kotschet, S. Hodgkinson,
T.A. Hardy, M.B. Delatycki, R.A. Hajj-Ali, P.H. Kothari, S.F. Nelson,
R.R. Frants, R.W. Baloh, M.D. Ferrari and J.P. Atkinson C-terminal
truncations in human 3[prime]-5[prime] DNA exonuclease TREX1 cause
autosomal dominant retinal vasculopathy with cerebral leukodystrophy,
Nat Genet 39 (2007) 1068-1070.
[53] S.-i. Tsukumo and K. Yasutomo DNaseI in pathogenesis of systemic lupus
erythematosus, Clinical Immunology 113 (2004) 14-18.
[54] A.L. Brennan and D.M. Geddes Bringing new treatments to the bedside
in cystic fibrosis, Pediatric Pulmonology 37 (2004) 87-98.
23
Figure 1
Exo
1
Exo
2
Exo
3
PPI
I
TM
H
N C
